Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stable Chelation of Zr-89 and Ac-225 with Dual Size-Selective Macrocyclic py<sub>2</sub>-macrodipa for <sup>225</sup>Ac/<sup>89</sup>Zr Paired Theranostics.

Inorganic chemistry·2026
Same author

Development of a Highly Effective Bifunctional Ligand 2E-C-NETA for Targeted Lu-177 Therapy: Synthesis, Radiolabeling, In Vitro Stability, and In Vivo Biodistribution.

ChemMedChem·2026
Same author

Exploratory FDG PET/CT Imaging in mCRPC Patients Treated with Sipuleucel-T ± IL-7: A Phase II Trial Subanalysis.

International journal of molecular sciences·2026
Same author

Phosphinate or Urea? Synthesis and Biological Evaluation of Prostate Specific Membrane Antigen-Targeted Fluorophores With Different Zinc-Binding Motif.

ChemMedChem·2026
Same author

A Siderophore-Antibiotic Heterodimer Imaging Agent Enables <i>In Vivo</i> PET Imaging of <i>S. aureus</i> Infections.

Journal of medicinal chemistry·2026
Same author

Consortium on Bridging Radiation Segmentectomy (COBRAS): A Multicenter Study of Complete Pathologic Necrosis in Hepatocellular Carcinoma.

Radiology·2026

Related Experiment Video

Updated: Jul 7, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K

Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer.

Nadia Benabdallah1, Peng Lu1,2, Diane S Abou1

  • 1Mallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine, St. Louis, Missouri.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|December 21, 2023
PubMed
Summary
This summary is machine-generated.

Radium-223 chloride ([223Ra]RaCl2) uptake in bone metastases is uneven at the microscopic level. This finding is crucial for understanding alpha-particle therapy distribution and optimizing patient treatment strategies.

Keywords:
223Raautoradiographybiopsydosimetryα-particle

More Related Videos

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.9K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.2K

Related Experiment Videos

Last Updated: Jul 7, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.9K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.2K

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmaceutical therapy

Background:

  • Alpha-particle emitters offer potent cancer therapy due to high energy transfer and localized dose.
  • Limited data exists on radiopharmaceutical distribution at the alpha-particle pathlength scale.

Purpose of the Study:

  • To determine the distribution of [223Ra]RaCl2 in bone metastatic castration-resistant prostate cancer at the near-cell scale.
  • To inform activity distribution and dose calculations for alpha-particle therapy.

Main Methods:

  • Collected biopsy specimens and blood from 7 patients 24 hours post-[223Ra]RaCl2 administration.
  • Analyzed [223Ra] activity using quantitative autoradiography and micro-CT.
  • Performed automated segmentation, registration of histopathology, and MIRD-based dosimetry.

Main Results:

  • Observed significant differences in [223Ra] activity distribution across and within patient samples.
  • Confirmed localized high-activity regions amidst low-activity tissue at the microscopic level.
  • Found heterogeneous alpha-particle emission concentrated at bone-tissue interfaces, leading to nonuniform absorbed dose profiles.

Conclusions:

  • Patient data reveals nonuniform [223Ra] uptake in bone metastases at the small scale.
  • Spatially nonuniform dose estimates highlight opportunities and challenges for improving patient outcomes.
  • This study is a foundational step towards personalized alpha-particle radiopharmaceutical therapy.